COMPUGEN LTD
CGEN · Biological Products, (No Diagnostic Substances) · EDGAR filings ↗
Reference price $3.20 — last insider sale, 2026-04-24 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
C62Clinical-stage immuno-oncology biotech whose flattering profitability is a one-off licensing artifact.
Strengths
- Strong cash position: $99.9M, current ratio 6.6, FCF positive this period
- Partnered assets with AstraZeneca (rilvegostomig) and Gilead (GS-0321) provide milestone optionality
Risks
- Profitability/margins (op margin 100th, net margin 98.8th) driven by lumpy license revenue, not a durable business; net income growth -3.5 (3.8th)
- Lead COM902/TIGIT program effectively shelved on negative field data; key MAIA-ovarian readout not until 2027
- Going-concern-type language: history of losses, future dilution risk, Nasdaq minimum-bid risk
Notable findings
- Insider sellingInsider selling — 11 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2027-03 — PHASE1/PHASE2 · Ovarian Cancer
Key metrics
Gross margin
87.3%
Operating margin
43.1%
Net margin
48.6%
Return on equity
34.4%
Return on assets
22.6%
Revenue growth (QoQ)
161.1%
Current ratio
6.6×
Free cash flow
$31M
Tangible book value
$103M
Cash & investments
$100M
Stock comp / revenue
2.6%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-24 | Ophir Eran | Sell | 5.0K | $3.20 |
| 2026-04-24 | Levine Zurit | Option exercise | 2.0K | $1.15 |
| 2026-04-24 | Ophir Eran | Option exercise | 5.0K | $0.83 |
| 2026-04-24 | Levine Zurit | Sell | 2.0K | $3.20 |
| 2026-04-14 | Levine Zurit | Sell | 2.0K | $2.80 |
| 2026-04-14 | Ophir Eran | Option exercise | 5.0K | $0.83 |
| 2026-04-14 | Ophir Eran | Sell | 5.0K | $2.90 |
| 2026-04-14 | Levine Zurit | Option exercise | 2.0K | $1.15 |
| 2026-04-10 | Levine Zurit | Sell | 3.1K | $2.56 |
| 2026-04-10 | Levine Zurit | Option exercise | 1.1K | $0.83 |
| 2026-04-10 | Levine Zurit | Option exercise | 2.0K | $1.15 |
| 2026-04-10 | Levine Zurit | Sell | 3.1K | $2.56 |
| 2026-04-10 | Levine Zurit | Option exercise | 1.1K | $0.83 |
| 2026-04-10 | Levine Zurit | Option exercise | 2.0K | $1.15 |
| 2026-04-08 | Levine Zurit | Option exercise | 4.4K | $0.83 |
| 2026-04-08 | Levine Zurit | Option exercise | 1.0K | $1.15 |
| 2026-04-08 | Levine Zurit | Sell | 5.4K | $2.42 |
| 2026-04-07 | Levine Zurit | Sell | 2.5K | $2.30 |
| 2026-04-07 | Levine Zurit | Option exercise | 2.5K | $0.83 |
| 2026-04-01 | Levine Zurit | Option exercise | 1.0K | $1.15 |
| 2026-04-01 | Levine Zurit | Option exercise | 2.5K | $0.83 |
| 2026-04-01 | Levine Zurit | Sell | 3.5K | $2.20 |
| 2026-04-01 | Ophir Eran | Option exercise | 5.6K | $0.83 |
| 2026-04-01 | Ophir Eran | Sell | 5.6K | $2.21 |
| 2026-03-26 | Levine Zurit | Option exercise | 12K | $0.83 |
| 2026-03-26 | Levine Zurit | Sell | 12K | $2.04 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06759649 ↗ | A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies Neoplasm, Cancer, Malignant Tumors | PHASE1 | Recruiting | 2027-11-22 |
| NCT06888921 ↗ | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer Ovarian Cancer, Ovarian Cancer Recurrent | PHASE1/PHASE2 | Recruiting | 2027-03-01 |
| NCT04354246 ↗ | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies Advanced Cancer, Ovarian Cancer | PHASE1 | Completed | 2026-04-01 |
| NCT04570839 ↗ | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. Endometrial Neoplasms, Ovarian Cancer | PHASE1/PHASE2 | Completed | 2024-05-15 |
| NCT03667716 ↗ | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Advanced Cancer, Ovarian Cancer | PHASE1 | Completed | 2024-01-30 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (2)
Suppliers (0)
Named in the 10-K; linked when we track them.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-02 | 2025-12-31 | 0001178913-26-000663 ↗ |
| 20-F | 2025-03-04 | 2024-12-31 | 0001178913-25-000679 ↗ |
| 20-F | 2024-03-05 | 2023-12-31 | 0001178913-24-000818 ↗ |
| 20-F | 2023-02-28 | 2022-12-31 | 0001178913-23-000772 ↗ |
| 20-F | 2022-02-28 | 2021-12-31 | 0001178913-22-000846 ↗ |
| 20-F | 2021-02-25 | 2020-12-31 | 0001178913-21-000791 ↗ |
| 20-F | 2020-02-24 | 2019-12-31 | 0001178913-20-000625 ↗ |
| 20-F | 2019-03-21 | 2018-12-31 | 0001178913-19-000894 ↗ |
| 20-F | 2018-03-27 | 2017-12-31 | 0001178913-18-000965 ↗ |
| 20-F | 2017-02-16 | 2016-12-31 | 0001178913-17-000548 ↗ |
| 20-F | 2016-03-07 | 2015-12-31 | 0001178913-16-004622 ↗ |
| 20-F | 2015-03-12 | 2014-12-31 | 0001178913-15-000852 ↗ |